Alexandra K. Golant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandra K. Golant has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Danny Zakria
Icahn School of Medicine at Mount Sinai
2 shared publications- Emma Guttman-Yassky
Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY
2 shared publications - Mark Lebwohl
Icahn School of Medicine at Mount Sinai
2 shared publications - Marley Cutrona
Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY
2 shared publications - Amanda Loesch
Temple University
1 shared publication - April W. Armstrong
University of California, Los Angeles, USA
1 shared publication
Latest Publications
- 17 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9) , e70363
Atopic Dermatitis, Sleep Quality, and Cognitive Difficulties in US Adults: A 2024 NHIS Mediation Analysis
- 17 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9) , e70363
Atopic Dermatitis, Sleep Quality, and Cognitive Difficulties in US Adults: A 2024 NHIS Mediation Analysis
- Open Access
- 15 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (11) , 5793-5803
Roflumilast Cream for Residual Disease in Patients With Atopic Dermatitis on Dupilumab: A Retrospective Chart Review Study
Introduction Residual disease is relatively common in dupilumab-treated patients with atopic dermatitis (AD). Adjunctive topical treatment, including topical corticosteroids or non-steroidal treatments, are often needed. In this study, we evaluated the clinical characteristics and outcomes of patients with AD on dupilumab with residual disease who were subsequently treated with roflumilast cream. Methods This was a retrospective chart review conducted at a single academic center. Electronic medical records were searched to identify patients with AD who were prescribed dupilumab and were subsequently prescribed roflumilast cream for persistent or residual disease between July 2022 and January 2026. Results Of the 676 cases of AD identified and included in this review, there were 30 cases of dupilumab-treated patients with residual AD disease. One additional patient with de novo facial erythema on dupilumab was described qualitatively. Following roflumilast cream treatment, physician-documented clinical improvement was reported in 83% (25/30) of these patients. Of 18 patients with patient-reported outcomes, ten reported improvement with roflumilast cream (including resolution of disease, near resolution, or significant improvement with decreased flares); five reported reduced pruritus (1 with fully resolved itch); three reported no improvement; and one discontinued roflumilast cream due to burning. No additional adverse events were documented in the medical records. Conclusions In this retrospective case series, adjunctive roflumilast cream was associated with physician-documented clinical improvement in most dupilumab-treated patients with residual AD.
- 15 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (11) , 5793-5803
Open AccessRoflumilast Cream for Residual Disease in Patients With Atopic Dermatitis on Dupilumab: A Retrospective Chart Review Study
Introduction Residual disease is relatively common in dupilumab-treated patients with atopic dermatitis (AD). Adjunctive topical treatment, including topical corticosteroids or non-steroidal treatments, are often needed. In this study, we evaluated the clinical characteristics and outcomes of patients with AD on dupilumab with residual disease who were subsequently treated with roflumilast cream. Methods This was a retrospective chart review conducted at a single academic center. Electronic medical records were searched to identify patients with AD who were prescribed dupilumab and were subsequently prescribed roflumilast cream for persistent or residual disease between July 2022 and January 2026. Results Of the 676 cases of AD identified and included in this review, there were 30 cases of dupilumab-treated patients with residual AD disease. One additional patient with de novo facial erythema on dupilumab was described qualitatively. Following roflumilast cream treatment, physician-documented clinical improvement was reported in 83% (25/30) of these patients. Of 18 patients with patient-reported outcomes, ten reported improvement with roflumilast cream (including resolution of disease, near resolution, or significant improvement with decreased flares); five reported reduced pruritus (1 with fully resolved itch); three reported no improvement; and one discontinued roflumilast cream due to burning. No additional adverse events were documented in the medical records. Conclusions In this retrospective case series, adjunctive roflumilast cream was associated with physician-documented clinical improvement in most dupilumab-treated patients with residual AD.
- 10 April 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1792-1794
Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis–Eczema Overlap ( PsEma ): A Retrospective Study
- 10 April 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1792-1794
Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis–Eczema Overlap ( PsEma ): A Retrospective Study
- Open Access
- 8 November 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 68, 34-36
Lebrikizumab-induced psoriasis in a patient with atopic dermatitis
- 8 November 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 68, 34-36
Open AccessLebrikizumab-induced psoriasis in a patient with atopic dermatitis
- 6 September 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (12) , 2947-2949
Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy
- 6 September 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (12) , 2947-2949
Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy
- 14 March 2024
- Published by Springer Nature
- p. 15-23
Atopic Dermatitis and Internal Vessel Inflammation
- Open Access
- 14 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e24148
Impact of Coding Curriculum on Dermatology Resident Billing
Competent medical coding is key to maintaining a successful dermatology practice. Resident billing performance can have significant financial implications for the academic institutions employing them. During their residency training, dermatology residents commonly find themselves responsible for the billing of patient encounters. However, despite the importance of adequate knowledge and skill in medical coding, recent data show inadequacies in this aspect of resident education. The goal of this study is to evaluate the impact of an interventional coding curriculum on dermatology residents’ billing accuracy at our institution. Billing data, including evaluation and management (E/M) level of service, procedural codes, and current procedural terminology modifiers (if applicable) were queried from the electronic medical records (EMR) at a resident clinic seeing patients on three half-days each week. Billing codes were gathered from patient visits occurring in two separate time periods, before and after the intervention. The intervention consisted of monthly resident lectures on E/M and procedural billing in outpatient dermatology with associated quizzes. Billing accuracy was verified by three attending dermatologists through chart review and compared between the two time periods. Overall, billing data from 532 patient visits, 267 from the pre-intervention period and 265 from the post-intervention period, were checked for accuracy. The accuracy of resident-billed E/M levels of service was similar between the pre- and post-intervention periods (44.3% vs. 44.8%). Similar rates of undercoding and overcoding were noted between the pre- and post-intervention periods (35.2% undercoded and 8% overcoded vs. 35.7% and 8.9%, respectively). However, substantial improvements were noted in the rate of errors with procedural codes and modifiers in the post-intervention period. Overall, 21.9% of procedural codes were incorrectly billed pre-intervention compared to 3.7% post-intervention (p < 0.05). Moreover, 55.2% of modifiers were incorrectly billed pre-intervention versus 27.3% post-intervention (p < 0.05). Our analysis suggests that billing lectures yielded a clear improvement in resident billing accuracy at our institution. While there was no improvement in E/M coding, there was a significant improvement in the usage of procedural codes and modifiers. Similar analyses can be used by other residency programs to monitor resident billing performance and the efficacy of educational programs on medical billing.
- 14 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e24148
Open AccessImpact of Coding Curriculum on Dermatology Resident Billing
Competent medical coding is key to maintaining a successful dermatology practice. Resident billing performance can have significant financial implications for the academic institutions employing them. During their residency training, dermatology residents commonly find themselves responsible for the billing of patient encounters. However, despite the importance of adequate knowledge and skill in medical coding, recent data show inadequacies in this aspect of resident education. The goal of this study is to evaluate the impact of an interventional coding curriculum on dermatology residents’ billing accuracy at our institution. Billing data, including evaluation and management (E/M) level of service, procedural codes, and current procedural terminology modifiers (if applicable) were queried from the electronic medical records (EMR) at a resident clinic seeing patients on three half-days each week. Billing codes were gathered from patient visits occurring in two separate time periods, before and after the intervention. The intervention consisted of monthly resident lectures on E/M and procedural billing in outpatient dermatology with associated quizzes. Billing accuracy was verified by three attending dermatologists through chart review and compared between the two time periods. Overall, billing data from 532 patient visits, 267 from the pre-intervention period and 265 from the post-intervention period, were checked for accuracy. The accuracy of resident-billed E/M levels of service was similar between the pre- and post-intervention periods (44.3% vs. 44.8%). Similar rates of undercoding and overcoding were noted between the pre- and post-intervention periods (35.2% undercoded and 8% overcoded vs. 35.7% and 8.9%, respectively). However, substantial improvements were noted in the rate of errors with procedural codes and modifiers in the post-intervention period. Overall, 21.9% of procedural codes were incorrectly billed pre-intervention compared to 3.7% post-intervention (p < 0.05). Moreover, 55.2% of modifiers were incorrectly billed pre-intervention versus 27.3% post-intervention (p < 0.05). Our analysis suggests that billing lectures yielded a clear improvement in resident billing accuracy at our institution. While there was no improvement in E/M coding, there was a significant improvement in the usage of procedural codes and modifiers. Similar analyses can be used by other residency programs to monitor resident billing performance and the efficacy of educational programs on medical billing.